Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gilteritinib + venetoclax arm of the ALLG AMLM26 INTERCEPT trial for progressive acute myeloid leukemia
ACTRN12624000082505Phase 2Recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Dec 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of gilteritinib and venetoclax in acute myeloid leukemia (AML) (4 arms), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: MRD clearance rate. Started Dec 2024; status: recruiting.
02
Drugs
gilteritinibvenetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ACTRN12624000082505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000082505.